OncoMatch/Clinical Trials/NCT06377566
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Is NCT06377566 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for hodgkin lymphoma.
Treatment: Brentuximab vedotin · Doxorubicin · Vinblastine · Dacarbazine · Pembrolizumab · Gemcitabine · Vinorelbine — The purpose of this study is to test whether BV-AVD is an effective treatment in people with early stage, bulky Hodgkin lymphoma that was recently diagnosed and who have not yet received any treatments for their disease. BV is a type of drug called an antibody-drug conjugate (ADC). ADCs are a substance made up of a monoclonal antibody chemically linked to a drug. Antibodies are proteins made by the immune system to fight infections and other possible harms to the body. The monoclonal antibody binds to specific proteins or receptors found on certain types of cells, including cancer cells. The linked drug enters these cells and kills them without harming other cells. Researchers think BV may be an effective treatment for this type of cancer because the drug targets cells that have CD30, which play a role in cancer cell growth. By destroying these cells, BV may help slow or stop the growth of the cancer. AVD (doxorubicin, vinblastine, and dacarbazine) is a treatment regimen that works by stopping the growth of cancer cells, either by killing the cells or by stopping them from dividing. The researchers think that BV in combination with AVD may work better than AVD alone to slow or stop the growth of the cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hodgkin Lymphoma
Biomarker criteria
Required: CD30 overexpression
CD30-positive Hodgkin lymphoma
Disease stage
Required: Stage I, II
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic therapy
Exception: excluding corticosteroids
Prior systemic therapy or radiation therapy for Hodgkin lymphoma (excluding corticosteroids)
Cannot have received: radiation therapy
Exception: excluding corticosteroids
Prior systemic therapy or radiation therapy for Hodgkin lymphoma (excluding corticosteroids)
Lab requirements
Blood counts
Platelet count > 75,000/µL; Hemoglobin level > 7.0 mg/dL; Absolute neutrophil count > 1.0 K/µL
Kidney function
Serum creatinine clearance ≥ 30 mL/minute as estimated by the Cockcroft-Gault Method
Liver function
Transaminase levels ≤ 3 times the upper limit of normal (≤ 5x ULN if Gilbert's disease or hepatic involvement); Total bilirubin < 1.5x ULN (≤ 3x ULN if Gilbert's disease or hepatic involvement)
Cardiac function
Cardiac ejection fraction ≥ 50% as measured by echocardiogram
Cardiac ejection fraction < 50% as measured by echocardiogram. Platelet count ≤ 75,000/µL. Hemoglobin level ≤ 7.0 mg/dL. Absolute neutrophil count ≤ 1.0 K/µL. Serum creatinine clearance < 30 mL/minute as estimated by the Cockcroft-Gault Method. Transaminase levels > 3 times the upper limit of normal in the absence of a history of Gilbert's disease or hepatic involvement. In patients with Gilbert's disease, > 5 times the upper limit of normal is exclusionary. Total bilirubin ≥ 1.5 the upper limit of normal in the absence of a history of Gilbert's disease or hepatic involvement. In patients with Gilbert's disease, > 3 times the upper limit of normal is exclusionary.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Miami · Miami, Florida
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (All Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (All Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities) · Commack, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify